Abstract:Molecular biology techniques allowed access to non-culturable microorganisms, while studies using analytical chemistry, as Liquid Chromatography and Tandem Mass Spectrometry, showed the existence of a complex communication system among bacteria, signaled by quorum sensing molecules. These approaches also allowed the understanding of dysbiosis, in which imbalances in the microbiome diversity, caused by antibiotics, environmental toxins and processed foods, lead to the constitution of different diseases, as cancer. Colorectal cancer, for example, can originate by a dysbiosis configuration, which leads to biofilm formation, production of toxic metabolites, DNA damage in intestinal epithelial cells through the secretion of genotoxins, and epigenetic regulation of oncogenes. However, probiotic strains can also act in epigenetic processes, and so be use for recovering important intestinal functions and controlling dysbiosis and cancer mitigation through the metabolism of drugs used in chemotherapy, controlling the proliferation of cancer cells, improving the immune response of the host, regulation of cell differentiation and apoptosis, among others. There are still gaps in studies on the effectiveness of the use of probiotics, therefore omics and analytical chemistry are important approaches to understand the role of bacterial communication, formation of biofilms, and the effects of probiotics and microbiome on chemotherapy. The use of probiotics, prebiotics, synbiotics, and metabiotics should be considered as a complement to other more invasive and hazard therapies, such chemotherapy, surgery, and radiotherapy. The study of potential bacteria for cancer treatment, as the next-generation probiotics and Live Biotherapeutic Products, can have a controlling action in epigenetic processes, enabling the use of these bacteria for the mitigation of specific diseases through changes in the regulation of genes of microbiome and host. Thus, it is possible that a path of medicine in the times to come will be more patient-specific treatments, depending on the environmental, genetic, epigenetic and microbiome characteristics of the host.

The application prospects of probiotic Bifidobacterium in the tumor targeted therapy

Bifidobacterium modulation of tumor immunotherapy and its mechanism

Bacterial-based cancer therapy: An emerging toolbox for targeted drug/gene delivery

Intratumoral Microbiota as a Target for Advanced Cancer Therapeutics

Application of Tumor-Targeting Bacteria in the Treatment of Solid Tumor

Feasibility Between Bifidobacteria Targeting and Changes in the Acoustic Environment of Tumor Tissue for Synergistic HIFU

Probiotics Influence Gut Microbiota and Tumor Immune Microenvironment to Enhance Anti-Tumor Efficacy of Doxorubicin

Nanoparticles Conjugated with Bacteria Targeting Tumors for Precision Imaging and Therapy.

Targeting bacterial metabolites in tumor for cancer therapy: An alternative approach for targeting tumor-associated bacteria

An emerging strategy: probiotics enhance the effectiveness of tumor immunotherapy via mediating the gut microbiome

The Rational Engineered Bacteria Based Biohybrid Living System for Tumor Therapy

Microbiota in cancer: molecular mechanisms and therapeutic interventions

Systematic review on the role of the gut microbiota in tumors and their treatment

Recent advances in bacteria-mediated cancer therapy

Bacterial‐Mediated Tumor Therapy: Old Treatment in a New Context

Tweak to Treat: Reprograming Bacteria for Cancer Treatment

Hypoxic Tumor Radiosensitization Using Engineered Probiotics

Awareness of intratumoral bacteria and their potential application in cancer treatment

The application of bacteria-nanomaterial hybrids in antitumor therapy

Gut Microbiota Modulation in the Context of Immune-Related Aspects of Lactobacillus spp. and Bifidobacterium spp. in Gastrointestinal Cancers

Probiotics and live biotherapeutic products aiming at cancer mitigation and patient recover